Dendritic Cell Immunotherapy for Mesothelioma
Dendritic Cell Immunotherapy – MesoPher®
At Erasmus University Medical Center Rotterdam, a unique personalized form of immunotherapy has been developed. This therapy ‘trains’ the immune system of a patient to work against the mesothelioma tumor.
To this end, a specific type of immune cells, so-called dendritic cells, are obtained from the patients’ blood. Subsequently these cells are exposed to PheraLys®. PheraLys® is prepared from mesothelioma ‘cell lines’: cells originating from a variety of mesothelioma tumors, which have been cultured and characterized extensively in the laboratory.
PheraLys® equips the dendritic cells with a broad spectrum of capacities to attack the patients’ mesothelioma tumors. The final drug product MesoPher®, consisting of the patients’ own dendritic cells exposed to PheraLys®, is given back to the patient in a series of injections.